Skip to content

New & Improved? Insurers Say “Show Us The Data

Two empty orange prescription pill bottles with white caps, placed open, facing each other on a reflective black surface

Milvexian, the experimental blood thinner co-developed by Bristol Myers Squibb and Johnson & Johnson, may launch soon, but there are legitimate reasons to be cautious about its commercial prospects in the pharmaceutical landscape. The pharma landscape is highly competitive, with numerous alternatives already on the market that have established efficacy and safety profiles, posing a significant challenge to Milvexian’s acceptance. Insurers will ask a LOT of questions before granting coverage.

The regulatory environment remains stringent, and delays in the approval process could affect the entry of new pharmaceutical drugs into the market. Additionally, the uptake of new medications often hinges on healthcare providers’ willingness to adopt them and on patients’ perceptions of their safety and effectiveness. Ongoing clinical trials and published research will play a crucial role in shaping the opinions of both these key stakeholders, thus influencing the product’s overall success. As such, while the potential for Milvexian is undeniable, caution is warranted until its commercial trajectory becomes clearer.

Here are the biggest challenges.

1ne. The first Phase III trial failed

OK, the trial is past news, but the fallout remains with a skeptical market. The most significant setback occurred when the Phase III LIBREXIA-ACS trial was stopped early after an independent monitoring committee concluded milvexian was unlikely to outperform standard therapy in patients recovering from acute coronary syndrome (heart attacks and unstable angina). There were no major new safety concerns, but the drug simply wasn’t expected to provide enough additional clinical benefit. (BioPharma Dive)

For any cardiovascular drug, a failed Phase III study substantially reduces expected peak sales even if it was conducted a while ago. Physicians will have many questions and may be skeptical.

2wo. The Factor XI hypothesis is under pressure

Milvexian belongs to a new class of anticoagulants called Factor XIa inhibitors. The promise has been compelling:

  • maintain stroke prevention
  • significantly reduce bleeding
  • replace or complement current direct oral anticoagulants

However, several companies developing Factor XI inhibitors have experienced disappointing late-stage results in different indications, raising questions about whether inhibiting Factor XI consistently delivers meaningful clinical benefit. (BioPharma Dive)

3hree. It competes against one of the best drugs in medicine

Ironically, Bristol Myers already markets one of the world’s leading anticoagulants:

  • Eliquis

Eliquis has:

  • enormous physician familiarity
  • excellent efficacy
  • a strong safety profile
  • years of real-world evidence

For physicians to switch, milvexian would need to demonstrate either:

  • superior efficacy,
  • dramatically lower bleeding,
  • or meaningful convenience.

Being merely “similar” is unlikely to justify widespread adoption.

4our. The commercial window is narrowing

By the time Milvexian reaches market (if approved), several dynamics may reduce its opportunity:

  • generic competition for existing anticoagulants
  • Competing Factor XI programs
  • payer pressure to use lower-cost options

That makes blockbuster projections harder to achieve.

5ive. Investors have become more skeptical

Before the Phase III failure, analysts viewed milvexian as a potential multibillion-dollar product. After the ACS trial stopped early:

  • Bristol Myers shares declined.
  • Analysts reduced expectations.
  • Some questioned whether the disappointing ACS result might foreshadow challenges in other indications, although atrial fibrillation and stroke prevention remain biologically distinct. (fiercebiotech.com)

But It May Still Succeed If….

It is important not to overstate the negative case. Two pivotal studies remain ongoing:

  • Prevention of stroke in patients with Atrial fibrillation
  • secondary stroke prevention

These represent larger commercial opportunities than acute coronary syndrome, and they involve different patient populations and dosing strategies. Bristol Myers and Johnson & Johnson have continued investing in these trials because they believe the biology may be more favorable. (STAT)

The investment thesis for milvexian has clearly weakened because:

  • One major Phase III indication has already failed,
  • The Factor XI drug class has produced mixed clinical results,
  • Eliquis sets an exceptionally high efficacy and safety standard,
  • and commercial competition will be intense.

Its ultimate success now depends largely on whether the ongoing atrial fibrillation and stroke prevention trials demonstrate a clinically meaningful advantage—particularly reduced bleeding without sacrificing protection against thrombotic events. Those remaining trials are likely to determine whether milvexian becomes a niche therapy or a significant new anticoagulant.

Topics:

Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

Leave a Reply

Send this to a friend